GlassScriptPhysician profile
Jason Boutros
NPI 1942243563
$15,997.57
in general payments reported to CMS, 2019-2025
55 companies · $1,325 in 2025
The $1,325 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,296 · 2020: $2,477 · 2021: $3,825 · 2022: $2,270 · 2023: $1,841 · 2024: $1,964 · 2025: $1,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,130.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,878.12 | 2019-2025 | Breztri, Farxiga |
| Abbvie INC. | $1,618.83 | 2020-2025 | Linzess, Ubrelvy, Viberzi |
| Biohaven Pharmaceuticals, INC. | $1,235.71 | 2021 | |
| Lilly USA, LLC | $879.17 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Sanofi-Aventis U.S. LLC | $696.94 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $679.64 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $671.74 | 2019-2023 | Trulance, Xifaxan |
| Novo Nordisk INC | $600.59 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $551.14 | 2022-2025 | |
| Horizon Therapeutics Plc | $520.40 | 2019-2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $501.48 | 2019-2022 | |
| Allergan, INC. | $447.10 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $369.74 | 2023-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $357.05 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $350.87 | 2019-2021 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $341.17 | 2019-2025 | Linzess |
| Kowa Pharmaceuticals America, INC. | $319.22 | 2019-2025 | Zoryve, Livalo |
| E.R. Squibb & Sons, L.L.C. | $304.02 | 2019-2025 | Cobenfy, Eliquis, Camzyos |
| Abbott Laboratories | $261.36 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Redhill Biopharma INC. | $237.45 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $219.82 | 2020-2023 | Austedo Xr, Austedo |
| Hikma Pharmaceuticals USA | $168.71 | 2020-2023 | Mitigare, Ryaltris |
| Lundbeck LLC | $146.58 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $140.57 | 2023-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $134.27 | 2024-2025 | Caplyta |
| Nestle Healthcare Nutrition INC. | $131.95 | 2020-2021 | |
| Amgen INC. | $121.17 | 2021-2025 | Krystexxa |
| Scilex Pharmaceuticals INC. | $90.47 | 2021-2024 | Ztlido |
| Dexcom, INC. | $80.69 | 2023-2025 | Dexcom G6 Transmitter |
| Corium, LLC | $74.06 | 2022-2023 | Adlarity |
| Biogen, INC. | $67.24 | 2021 | |
| Axsome Therapeutics, INC. | $64.59 | 2024 | Auvelity |
| Alkermes, INC. | $60.76 | 2021-2022 | |
| Almatica Pharma LLC | $55.91 | 2021-2024 | Loreev Xr |
| Astellas Pharma US INC | $55.76 | 2019 | |
| Eisai INC. | $44.69 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $42.60 | 2022-2023 | Quviviq |
| Eyevance Pharmaceuticals LLC | $40.95 | 2021 | |
| Circassia INC. | $38.40 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.92 | 2020 | |
| Mannkind Corporation | $32.58 | 2019 | |
| Ardelyx, INC. | $31.83 | 2024 | Ibsrela |
| Gilead Sciences, INC. | $30.05 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $29.77 | 2025 | Dupixent |
| Ucb, INC. | $29.29 | 2020 | |
| Ani Pharmaceuticals, INC. | $27.94 | 2024 | Purified Cortrophin Gel |
| Biohaven Pharmaceutical Holding Company LTD. | $24.16 | 2022 | |
| Medtronic Minimed, INC. | $23.83 | 2019 | |
| Aimmune Therapeutics, INC. | $22.58 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $21.20 | 2025 | Rezdiffra |
| Corcept Therapeutics | $20.79 | 2024 | Korlym |
| Daiichi Sankyo INC. | $20.28 | 2019 | |
| Avanir Pharmaceuticals, INC. | $19.45 | 2022 | |
| Alk-Abello, INC | $17.43 | 2023 | Grastek, Odactra, Ragwitek |
| Upsher-Smith Laboratories LLC | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Boutros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.